STOCK TITAN

Smith+Nephew to showcase advanced Orthopaedic Reconstruction technologies for Robotics, Knees, Hips, and Shoulders at AAOS 2025  

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

Smith+Nephew (NYSE:SNN) announces its showcase of advanced Orthopaedic Reconstruction technologies at the AAOS 2025 Annual Meeting in San Diego. The company highlights several key innovations:

The CORIOGRAPH Pre-Op Planning and Modeling Services now includes support for hip procedures, featuring simulation of patient-specific daily activities. The CORI Digital Tensioner enhances knee procedure personalization through objective gap data measurements.

The new CATALYSTEM Primary Hip System is designed for modern primary hip surgery, particularly anterior approach procedures. The company's OXINIUM on highly cross-linked polyethylene demonstrates >94.1% survivorship over 20 years in total hip arthroplasty.

Additionally, SNN introduces OXINIUM technology on the LEGION Hinged Knee System and receives FDA 510(k) clearance for the AETOS Stemless anatomic total shoulder system, designed for efficient procedures with maximized metaphyseal fixation.

Smith+Nephew (NYSE:SNN) annuncia la sua vetrina di tecnologie avanzate per la ricostruzione ortopedica all'Annual Meeting AAOS 2025 a San Diego. L'azienda mette in evidenza diverse innovazioni chiave:

I Servizi di Pianificazione e Modellazione Pre-Op CORIOGRAPH ora includono supporto per procedure all'anca, con simulazione delle attività quotidiane specifiche per il paziente. Il Tensore Digitale CORI migliora la personalizzazione delle procedure al ginocchio attraverso misurazioni oggettive dei dati di gap.

Il nuovo CATALYSTEM Primary Hip System è progettato per la moderna chirurgia primaria dell'anca, in particolare per le procedure di approccio anteriore. L'ossido di zirconio OXINIUM su polietilene altamente reticolato dimostra una sopravvivenza >94,1% dopo 20 anni in artroplastica totale dell'anca.

Inoltre, SNN introduce la tecnologia OXINIUM sul LEGION Hinged Knee System e riceve l'approvazione FDA 510(k) per il sistema anatomico per spalla totale AETOS Stemless, progettato per procedure efficienti con fissazione metafisaria massimizzata.

Smith+Nephew (NYSE:SNN) anuncia su exhibición de tecnologías avanzadas de Reconstrucción Ortopédica en la Reunión Anual AAOS 2025 en San Diego. La compañía destaca varias innovaciones clave:

Los Servicios de Planificación y Modelado Pre-Op CORIOGRAPH ahora incluyen soporte para procedimientos de cadera, con simulación de actividades diarias específicas del paciente. El Tensores Digital CORI mejora la personalización de los procedimientos de rodilla a través de mediciones objetivas de datos de espacio.

El nuevo Sistema Primario de Cadera CATALYSTEM está diseñado para la cirugía primaria moderna de cadera, particularmente para procedimientos de abordaje anterior. El OXINIUM en polietileno altamente reticulado demuestra una supervivencia >94,1% durante 20 años en artroplastia total de cadera.

Además, SNN presenta la tecnología OXINIUM en el Sistema de Rodilla Hinge LEGION y recibe la aprobación de la FDA 510(k) para el sistema anatómico de hombro total AETOS Stemless, diseñado para procedimientos eficientes con fijación metafisaria maximizada.

Smith+Nephew (NYSE:SNN)는 샌디에이고에서 열리는 AAOS 2025 연례 회의에서 첨단 정형외과 재건 기술을 선보인다고 발표했습니다. 이 회사는 여러 가지 주요 혁신을 강조합니다:

CORIOGRAPH 수술 전 계획 및 모델링 서비스는 이제 고관절 수술을 지원하며, 환자 맞춤형 일상 활동 시뮬레이션을 제공합니다. CORI 디지털 텐셔너는 객관적인 갭 데이터 측정을 통해 무릎 수술 개인화를 향상시킵니다.

새로운 CATALYSTEM 기본 고관절 시스템은 현대적인 기본 고관절 수술, 특히 전방 접근 수술을 위해 설계되었습니다. 고도로 교차 연결된 폴리에틸렌에서의 OXINIUM은 총 고관절 전치환술에서 20년 동안 >94.1%의 생존율을 보여줍니다.

또한, SNN은 LEGION 힌지 무릎 시스템에 OXINIUM 기술을 도입하고, 효율적인 절차를 위해 최대의 메타피지얼 고정을 설계한 AETOS 스템리스 해부학적 총 어깨 시스템에 대해 FDA 510(k) 승인을 받았습니다.

Smith+Nephew (NYSE:SNN) annonce sa vitrine de technologies avancées de reconstruction orthopédique lors de la réunion annuelle AAOS 2025 à San Diego. L'entreprise met en avant plusieurs innovations clés :

Les Services de Planification et de Modélisation Pré-Op CORIOGRAPH incluent désormais un soutien pour les procédures de hanche, avec simulation des activités quotidiennes spécifiques au patient. Le Tenseur Numérique CORI améliore la personnalisation des procédures du genou grâce à des mesures objectives des données d'écart.

Le nouveau Système de Hanche Primaire CATALYSTEM est conçu pour la chirurgie de hanche primaire moderne, en particulier pour les procédures d'approche antérieure. L'OXINIUM sur polyéthylène hautement réticulé démontre une survie de >94,1% sur 20 ans en arthroplastie totale de la hanche.

De plus, SNN introduit la technologie OXINIUM sur le Système de Genou Hinge LEGION et reçoit l'approbation FDA 510(k) pour le système anatomique de l'épaule totale AETOS Stemless, conçu pour des procédures efficaces avec une fixation métaphysaire maximisée.

Smith+Nephew (NYSE:SNN) kündigt die Präsentation fortschrittlicher Technologien zur orthopädischen Rekonstruktion auf der AAOS-Jahrestagung 2025 in San Diego an. Das Unternehmen hebt mehrere wichtige Innovationen hervor:

Die CORIOGRAPH Prä-OP-Planungs- und Modellierungsdienste bieten jetzt Unterstützung für Hüftoperationen und beinhalten die Simulation von patientenspezifischen Alltagsaktivitäten. Der CORI digitale Spannungsregler verbessert die Personalisierung von Knieoperationen durch objektive Messungen von Lücken.

Das neue CATALYSTEM Primär-Hüftsystem ist für moderne primäre Hüftoperationen, insbesondere für Verfahren mit anteriorem Zugang, konzipiert. Das OXINIUM auf hochvernetztem Polyethylen zeigt eine Überlebensrate von >94,1% über 20 Jahre bei der totalen Hüftarthroplastik.

Darüber hinaus führt SNN die OXINIUM-Technologie im LEGION Gelenk-Kniesystem ein und erhält die FDA 510(k)-Zulassung für das AETOS Stemless anatomische totale Schulter-System, das für effiziente Verfahren mit maximaler metaphysärer Fixierung entwickelt wurde.

Positive
  • OXINIUM technology shows exceptional >94.1% survivorship rate over 20 years in hip replacements
  • FDA 510(k) clearance received for new AETOS Stemless shoulder system
  • Expansion of CORIOGRAPH platform to include hip procedures
  • Launch of new CATALYSTEM Hip System optimized for modern surgical approaches
Negative
  • None.

Insights

Smith+Nephew's showcase at AAOS 2025 highlights several significant advancements that strengthen their competitive position in the $19.4 billion orthopedic reconstruction market. The FDA 510(k) clearance for their AETOS Stemless anatomic total shoulder represents a strategic entry into the growing stemless shoulder segment, addressing surgeon preference for less invasive procedures with smaller operating room footprints.

Their CORIOGRAPH platform's expansion to support hip procedures creates a more comprehensive robotic ecosystem, critical as robotic-assisted surgeries continue gaining market share. The platform's differentiated capability to simulate patient-specific activities of daily living provides a competitive advantage in the personalized medicine space.

The Australian Joint Registry data showing OXINIUM on highly cross-linked polyethylene with >94.1% survivorship over 20 years represents exceptionally strong clinical evidence that should support premium pricing and market share gains in hip reconstruction. This proven technology's expansion to the LEGION Hinged Knee System addresses the higher-margin revision knee segment.

The new CATALYSTEM Primary Hip System specifically designed for anterior approach procedures strategically targets one of the fastest-growing surgical technique preferences among orthopedic surgeons. The system's reduced distal geometry reflects the industry shift toward bone-preserving implants that maintain future revision options for younger patients.

Collectively, these innovations strengthen Smith+Nephew's competitive positioning in key growth segments of orthopedic reconstruction, with particular emphasis on personalization, robotics integration, and clinically-validated materials technology.

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will feature the latest advancements in Orthopaedic Reconstruction at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego this week. Some of the highlighted technologies will include:


Robotics: Optimizing and personalizing surgery

With CORIOGRAPH Pre-Op Planning and Modeling Services advanced technology and the CORI Surgical System's image-agnostic solution for robotic-assisted knee and computer-guided hip replacement procedures, Smith+Nephew offers a highly personalized approach for both surgeons and their patients. CORIOGRAPH’s recent addition of support for hip procedures expands the platform’s reach to provide advanced planning and simulation technology for THA. A defining feature of the technology is the ability to simulate a patient’s functional activities of daily living (ADLs) specific to their anatomy.1

Alongside these advancements, the CORI Digital Tensioner enhances the level of personalization in knee procedures by providing objective gap data for planning and execution of the procedure.2-4 Now available for UKA, TKA, and Revision TKA, the CORI Digital Tensioner is designed to deliver accurate gap balance measurements with the CORI Surgical System for optimizing the surgical plan to align with each patient’s unique soft tissue anatomy.

These cutting-edge technologies enable a highly personalized and tailored surgical approach with the CORI Surgical System, ensuring that patient-specific needs are met. Learn more by visiting the CORIOGRAPH  webpage here.

                                        

Hips: Best-in-class just got better

Smith+Nephew’s new CATALYSTEM Primary Hip System is designed to address the evolving demands of primary hip surgery - including the increased adoption of anterior approach procedures. It features a triple-taper stem design with uniform proximal loading,5 and the reduced distal stem geometry and shorter lengths are ideal for anterior approach - and suitable for all approaches.6

Smith+Nephew’s total hip arthroplasty (THA) portfolio was recently recognized in the latest annual report from the Australian Orthopaedic Association National Joint Replacement Registry. It highlighted the exceptional performance of proprietary OXINIUM (Oxidized Zirconium) on highly cross-linked polyethylene where the data indicated the combination has the highest survivorship rate (>94.1%) among all bearing combinations over a 20-year period for THA.7 Read the press release here.


Knees: Raising the bar in revisions

Smith+Nephew recently launched proprietary OXINIUM implant technology on the LEGION Hinged Knee (HK) System that delivers the durability of metals, the wear resistance of ceramics, and corrosion resistance better than both metal and ceramic.8-14 Part of the LEGION Total Knee (TK) System, the LEGION HK System is designed to provide a natural range of motion with medial pivot, lateral roll back, and screw home. Since 2011, the LEGION HK System has enabled surgeons to transition intraoperatively from a constrained revision knee implant to a CoCr-hinged assembly. Learn more by visiting the LEGION HK webpage here.


AETOS Shoulder System: Elegant design. Elevated experience.

Smith+Nephew recently received 510(k) clearance from the FDA for a stemless anatomic total shoulder for the AETOS Shoulder System (AETOS Stemless). AETOS Stemless addresses the growing demand for anatomic total shoulder replacement with a small operating room footprint allowing for an efficient procedure.15 It is designed to maximize metaphyseal fixation and stability with an inlay collar, cruciate fins, and porous titanium coating to encourage biological fixation.16,17 Learn more by visiting the AETOS webpage here.

To learn more about Smith+Nephew’s advanced solutions for Orthopaedic Reconstruction, please visit our booth (#3729) at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in San Diego March 11-13, 2025 or visit wwww.smith-nephew.com.

 - ends –

 

 

Media Enquiries

Dave Snyder          +1 (978) 749-1440 

Smith+Nephew      david.snyder@smith-nephew.com

 

References

  1. Smith+Nephew 2020. Internal Report. EA/RECON/VISIONAIRE/001/v6.
  2. Smith+Nephew 2022. Optimus TKA Tensioner Gap Assessment Verification Report. Internal Report. 10059269.
  3. Smith+Nephew 2022. Tensioner KPC: Tensioner Calibration Check. Internal Report. TR100116, REV B.
  4. Smith+Nephew 2022. CORI TENSIONER. 2020.04 Study Cases. Preliminary Analysis Report REV B.
  5. Smith + Nephew 2024. Finite Element Analysis of the CATALYSTEM Hip Stem Design. Internal Report. OR-24-025
  6. Smith + Nephew 2024. Surgeon Feedback on the CATALYSTEM Total Hip System. Internal Report.  CSD.REC.24.001
  7. Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) Hip, Knee & Shoulder Arthroplasty: 2024 Annual Report Adelaide; AOA, 2024:1–629. Available at: https://aoanjrr.sahmri.com/annual-reports-2024. Accessed December 11, 2024.
  8. Sheth NP, Lementowski P, Hunter G, Garino JP. Clinical applications of oxidized zirconium. J Surg Orthop Adv. 2008;17(1):17-26.
  9. Davidson JA, Mishra AK, Poggie RA. Friction and UHMWPE wear of cobalt alloy, zirconia, titanium nitride, and amorphous diamond-like carbon implant bearing surfaces. Poster presented at: 4th World Biomaterials Con1992; Berlin, FRG.
  10. Hobbs L, Rozen V, Mangin S, Treska M. Oxidation Microstructures and Interfaces in the Oxidized Zirconium Knee. Int J Appl Ceram Technol. 2005.
  11. Long M, Riester L, Hunter G. Nano-Hardness Measurements of Oxidized Zr.2.5Nb and Various Orthopaedic Materials. 1998.
  12. Smith+Nephew 2010. Hip Simulator Wear Testing of XLPE Liners Against Oxidized Zr-2.5Nb and BIOLOX Delta Heads. Interal Report. OR-10-155
  13. Smith+Nephew 2010. OR-10-155.
  14. Smith+Nephew 2016. OR-16-127
  15. Smith+Nephew 2023. AETOS Instruments & Trays.
  16. Internal Report. ER-04-0990-0020 REV B
  17. Pilliar RM. Cementless implant fixation—toward improved reliability. Orthopedic Clinics of North America. 2005;36(1):113-119

       

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.

 

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.

.

 


FAQ

What is the survivorship rate of Smith+Nephew's OXINIUM technology in hip replacements?

According to the Australian Orthopaedic Association Registry, SNN's OXINIUM on highly cross-linked polyethylene shows >94.1% survivorship rate over 20 years in total hip arthroplasty.

What new FDA clearance did Smith+Nephew (SNN) receive for shoulder surgery?

SNN received FDA 510(k) clearance for the AETOS Stemless anatomic total shoulder system, designed for efficient procedures with metaphyseal fixation.

What are the key features of SNN's new CATALYSTEM Hip System?

The CATALYSTEM features a triple-taper stem design with uniform proximal loading and reduced distal stem geometry, optimized for anterior approach procedures.

How does the CORIOGRAPH system enhance surgical planning for SNN procedures?

CORIOGRAPH provides advanced planning and simulation technology, including patient-specific daily activity simulations and support for both knee and hip procedures.
Smith & Nephew

NYSE:SNN

SNN Rankings

SNN Latest News

SNN Stock Data

13.02B
436.42M
0.03%
7.49%
0.49%
Medical Devices
Healthcare
Link
United Kingdom
Watford